Psilocybin: Clinical Trials

100 trials of Psilocybin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed, 35 recruiting, 10 active not recruiting, 9 not yet recruiting. 100 Phase 1, 18 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1100Completed 35, Recruiting 35, Active not recruiting 10, Not yet recruiting 9, Terminated 5, Unknown 3, Withdrawn 3
Phase 218Recruiting 7, Completed 4, Not yet recruiting 3, Active not recruiting 2, Terminated 1, Unknown 1

Follow Psilocybin: new trials by email Literature Review of Psilocybin trials Research Report on Psilocybin

Trials (filtered) newest first · largest first

All 100 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Psilocybin After Trauma Surgery for Pain
Psilocybin (Usona Institute), Postoperative analgesia - Pain Management, Postoperative Pain
Phase 1Not yet recruitingTrent Emerick702027-12-312026-08-06
The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin
0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink - Psilocybin Intoxication
Phase 1Not yet recruitingJohns Hopkins University802027-03-012026-10-16
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
Psilocybin - Treatment Resistant Depression, Substance Use Disorders
Phase 1 / Phase 2Not yet recruitingIndiana University502027-02-012026-10-23
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
Psilocybin, Saline Placebo, Clonidine - Well-Being, Psychological, Psychedelic Experiences
Phase 1Not yet recruitingUniversity of Wisconsin, Madison1202027-02-012026-10-30
ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder
Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy - Borderline Personality Disorder, Borderline Personality Pathology
Phase 1Not yet recruitingUniversity of Minnesota182026-12-012026-09-22
The Effects of Psilocybin on Social Connectedness
Psilocybin, Placebo - Loneliness, Grief
Phase 1Not yet recruitingYale University512026-12-012026-11-12
Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life
Psilocybin (Usona Institute) - Aging, Longevity
Phase 1RecruitingCharles Raison502026-11-162026-11-17
Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study
Psilocybin (Usona Institute) - Chronic Pelvic Pain
Phase 1RecruitingOregon Health and Science University152026-11-012026-09-23
Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation
Psilocybin (Usona Institute), Inactive Placebo (Usona Institute) - Phase I
Phase 1RecruitingBrown University242026-11-012026-10-08
Psilocybin for Amblyopia - Targeting Critical Periods in Humans
Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin - Amblyopia
Phase 1 / Phase 2RecruitingJohns Hopkins University242026-11-012026-11-05
Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Psilocybin, Pimavanserin, Inactive Placebo - Mood (Psychological Function), Well Being
Phase 1 / Phase 2RecruitingJohns Hopkins University202026-10-292026-11-02
Psilocybin for Treatment of OCD-2
Low Dose Psilocybin, High Dose Psilocybin - Obsessive - Compulsive Disorder
Phase 1 / Phase 2Not yet recruitingFrancisco A Moreno202026-09-082026-05-12
The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.
Psilocybin (drug), Placebo - Healthy Participants, Placebo - Control
Phase 1Not yet recruitingGabriella Gobbi502026-09-012026-02-25
Psilocybin as a Novel Therapy for Residual Anhedonia
Psilocybin, Placebo - Anhedonia, Emotional Blunting
Phase 1RecruitingNYU Langone Health902026-09-012026-09-15
The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function
Placebo, Psilocybin 15mg - Healthy
Phase 1 / Phase 2Not yet recruitingManoj Doss482026-09-012026-06-15
Psilocybin to Treat Depression in Spinal Cord Injury
Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder
Phase 1 / Phase 2RecruitingJames J. Peters Veterans Affairs Medical Center302026-08-062026-08-10
A Study of Psychedelics in Healthy Older Adults With Low Well-being
Psilocybin (drug), Dextromethorphan (DXM) - Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Phase 1RecruitingJennifer Mitchell802026-06-012026-09-09
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg - Obsessive-Compulsive Disorder
Phase 1RecruitingFrancisco A Moreno302026-05-182026-07-23
Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder
Psilocybin - PTSD
Phase 1RecruitingUniversity of New Mexico362026-05-012026-05-22
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
Psilocybin (Usona Institute) - Healthy Volunteer, Older Adults (65-85 Years)
Phase 1RecruitingUniversity of Colorado, Denver402026-04-012026-09-16

Showing 20 of 100. Sign in to see all of them.

Conditions studied

Depression (13)  ·  Obsessive-Compulsive Disorder (7)  ·  Stress Disorders, Post-Traumatic (6)  ·  Anxiety Disorders (4)  ·  Substance-Related Disorders (4)  ·  Depressive Disorder, Treatment-Resistant (3)  ·  Anhedonia (2)  ·  Anorexia Nervosa (2)  ·  Burnout, Psychological (2)  ·  Chronic Pain (2)  ·  Cluster Headache (2)  ·  Depressive Disorder, Major (2)  ·  Migraine Disorders (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)

Sponsors

Johns Hopkins University (18)  ·  Yale University (10)  ·  University of Wisconsin, Madison (9)  ·  University Hospital, Basel, Switzerland (5)  ·  MycoMedica Life Sciences PBC (3)  ·  Centre for Addiction and Mental Health (2)  ·  Francisco A Moreno (2)  ·  Gitte Moos Knudsen (2)  ·  Imperial College London (2)  ·  NYU Langone Health (2)  ·  University of California, Berkeley (2)  ·  University of California, Los Angeles (2)  ·  University of California, San Diego (2)  ·  University of Colorado, Denver (2)  ·  University of Minnesota (2)

Countries

United States (73)  ·  Canada (7)  ·  Switzerland (6)  ·  United Kingdom (5)  ·  Australia (2)  ·  Denmark (2)  ·  Austria (1)  ·  Brazil (1)  ·  Israel (1)

Top investigators

Charles Raison, MD (4)  ·  Benjamin Kelmendi, MD (3)  ·  Frederick S Barrett, PhD (3)  ·  Roland R Griffiths, Ph.D. (3)  ·  Christopher Nicholas, PhD (2)  ·  Francisco Moreno, MD (2)  ·  Joshua Woolley, MD/PhD (2)  ·  Matthias E Liechti, Prof. Dr. MD (2)  ·  Paul Hutson, PharmD (2)  ·  Albert Garcia-Romeu, Ph.D. (1)  ·  Albert Garcia-Romeu, PhD (1)  ·  Ali J. Zarrabi, MD (1)  ·  Anahita Bassir Nia, MD (1)  ·  Anthony Back (1)  ·  Anthony Bossis, PhD (1)

Results publications

PMID 17196053, PMID 20819978, PMID 28353056, PMID 29020861, PMID 29945469, PMID 33150319, PMID 33184743, PMID 34744825, PMID 36881769, PMID 37181888, PMID 37231080, PMID 37302533, PMID 38264632, PMID 38581739, PMID 39499526, PMID 40046861, PMID 40051480, PMID 40051582, PMID 40658345, PMID 40972137, PMID 41459830, PMID 41617652, PMID 41741501, PMID 41819589, PMID 41825921, PMID 42049943, PMID 42212900, PMID 42395285, PMID 42457666, PMID 42649324, PMID 42668404, PMID 42797541

NIH funding

R34AT013077 (2), K23MH122777 (1), P30CA138292 (1), R01DA066452 (1), R01MH142698 (1), R03DA042336 (1), R21DA046030 (1), R33AT012317 (1), UG3AG094957 (1)